News - Vaccibody.com

November 25, 2020 Co-founder, President and CSO Agnete Fredriksen receives the Research Council of Norway’s Innovation Award

Posted at 12:45h in Uncategorized

Co-founder, President and CSO Agnete Fredriksen receives the Research Council of Norway’s Innovation Award View press release (PDF)...

November 12, 2020 Vaccibody to present at Jefferies Virtual Healthcare Conference (November 17-19, 2020)

Posted at 11:04h in Uncategorized

Vaccibody to present at Jefferies Virtual Healthcare Conference View press release (PDF)...

November 6, 2020 Vaccibody announces the closing of the worldwide license and collaboration agreement with Genentech

Posted at 14:38h in Uncategorized

Following the expiration of the HSR Act waiting period, the collaboration agreement with Genentech is now effective View press release (PDF)...

October 7, 2020 Vaccibody Lists on Oslo Stock Exchange’s Merkur Market

Posted at 09:40h in Uncategorized

Vaccibody Lists on Oslo Stock Exchange’s Merkur Market View press release (PDF)...

October 1, 2020 Vaccibody announces Update on Expanded R&D Focus and Strategy

Posted at 06:41h in Uncategorized

Update on Expanded R&D Focus and Strategy View press release (PDF)...

October 1, 2020 Vaccibody enters into worldwide license and collaboration agreement with Genentech, a member of the Roche Group, to develop individualized neoantigen cancer vaccines

Posted at 06:38h in Uncategorized

Vaccibody enters into worldwide, exclusive license and collaboration agreement with Genentech to develop VB10.NEO, individualized neoantigen cancer vaccines View press release (PDF)...

August 27, 2020 QUARTERLY REPORT – 2020 Q2

Posted at 11:48h in quarterly-reports

QUARTERLY REPORT – 2020 Q2 (PDF)...

August 21, 2020 VACCIBODY FINALIZES PATIENT ENROLMENT IN VB N-01 PHASE I/IIa TRIAL WITH ITS NOVEL VB10.NEO NEOANTIGEN CANCER VACCINE

Posted at 08:02h in Uncategorized

VACCIBODY FINALIZES PATIENT ENROLMENT IN VB N-01 PHASE I/IIa TRIAL View press release (PDF)...

August 12, 2020 VACCIBODY AND NEKTAR THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1/2A STUDY ARM EVALUATING VB10.NEO IN COMBINATION WITH BEMPEGALDESLEUKIN

Posted at 13:02h in Uncategorized

First patient dosed in VB N-01 study arm with VB10.NEO plus Bempegaldesleukin (NKTR-214) View press release (PDF)...

July 7, 2020 Minutes from Extraordinary General Meeting in Vaccibody AS

Posted at 08:00h in Uncategorized

Minutes from Extraordinary General Meeting in Vaccibody AS...